Market Performance Overview
As of March 2, 2026, Amgen Inc. (ticker symbol: AMGN) experienced a notable day in the stock market. The stock opened at $388.00 and closed at $385.70, marking a decrease of $2.46 or approximately 0.63% from the previous closing price of $388.16. Throughout the trading session, the stock reached an intraday high of $391.29 and a low of $381.89, indicating a trading range of about $9.40. The total trading volume for the day was approximately 2.836 million shares, contributing to a market value of around $2.079 billion.
The performance of Amgen's stock today reflects a slight decline, which can be attributed to several factors including market sentiment and specific company news. The stock's opening price was slightly below the previous day's close, and despite reaching a high of $391.29, it ultimately closed lower. This indicates that while there was some bullish activity early in the day, selling pressure prevailed as the session progressed.
Key News and Events
- 46th Annual TD Cowen Health Care Conference: Amgen participated in this conference today, where Kave Niksefat, Senior Vice President of Global Marketing and Access, and Justin Claeys, Senior Vice President of Investor Relations, presented. The conference is a significant event for healthcare companies, providing a platform for discussing business strategies and future outlooks. Details about the presentation can be found in the official press release here.
- Regulatory Approvals: Amgen's recent regulatory achievements were highlighted, including the approval of UPLIZNA® for generalized myasthenia gravis by the European Commission. This approval is expected to enhance Amgen's portfolio and potentially drive future revenue growth.
- Financial Performance: Although the earnings report was released earlier on February 3, 2026, its implications continue to resonate in the market. The report indicated a significant increase in revenues and earnings per share (EPS) for the fourth quarter of 2025. Total revenues reached $9.9 billion, a 9% increase year-over-year, and GAAP EPS rose to $2.45, up 111% from the previous year. Such strong financial performance typically bolsters investor confidence, although the market reaction today suggests a cautious sentiment.
- Market Sentiment: The overall market environment today may have played a role in Amgen's stock performance. Broader market trends, including investor sentiment towards the biotech sector, can influence individual stock movements. Any negative news or uncertainty in the market can lead to profit-taking, particularly after a strong earnings report.
Conclusion
In summary, Amgen Inc. closed at $385.70 on March 2, 2026, reflecting a slight decline from the previous trading day. The stock's intraday movement showcased volatility, with a high of $391.29 and a low of $381.89. Key events, including participation in the TD Cowen Health Care Conference and recent regulatory approvals, are significant for the company's outlook. However, the market's overall sentiment and potential profit-taking may have contributed to the stock's decline today. Investors will likely continue to monitor Amgen's performance closely, especially in light of its recent financial results and ongoing developments in the healthcare sector.
Explore more exclusive insights at nextfin.ai.
